Pengwei Ren

Pengwei Ren

Auto-generated profile, based on publicly available information

Pengwei Ren

Department of Clinical Research Center for Respiratory Diseases, West China Hospital, Sichuan University

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
CWChengdi Wang
Chengdi Wang
WQWenliang Qiao
Wenliang Qiao
YJYuting Jiang
Yuting Jiang
MZMin Zhu
Min Zhu
JSJun Shao
Jun Shao
WLWeimin Li
Weimin Li
Immune checkpoint inhibitors (ICIs) have shown promising efficacy in the treatment of non‐small cell lung cancer (NSCLC). Sex‐associated dimorphism in immune system response is acknowledged, but the effect of patients’ sex on efficacy of ICIs as treatment in NSCLC still remains controversial. The present study was conducted to investigate the difference in efficacy of NSCLC patients receiving immune checkpoint inhibitors according to the sex. A total of 9583 patients involved 6567 men and 3016 women with advanced lung cancer from 15 randomized controlled trials were included in this study. An overall survival (OS) benefit of immune checkpoint inhibitors was illustrated in both male (HR 0.76, 95% CI 0.71‐0.82) and female (HR 0.73, 95% CI 0.58‐0.91) patients, and a progression‐free survival (PFS) benefit was also found in both men (HR 0.67, 95% CI 0.58‐0.77) and women (HR 0.73, 95% CI 0.56‐0.95) in NSCLC. Both PD‐1/PD‐L1 inhibitors alone and PD‐1/PD‐L1 plus chemotherapy significantly improved the OS and PFS in male patients. Whereas in females, PD‐1 inhibitors or monotherapy significantly benefited the OS but not the PFS, PD‐L1 inhibitors or combination therapy significantly prolonged the PFS but not the OS. No survival benefit was found in both male and female patients from the CTLA‐4 inhibitors. The current study indicated that the magnitude of survival benefit is sex‐dependent and male patients seemed to obtain more consistent and favorable outcomes from ICIs than women patients in NSCLC.

11 December 2015 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
LLLun-Xin Liu
Lun-Xin Liu
CZChang-Wei Zhang
Chang-Wei Zhang
PRPeng-Wei Ren
Peng-Wei Ren
SXShou-Wei Xiang
Shou-Wei Xiang
DXDing Xu
Ding Xu
HZHeng Zhang
Heng Zhang

1 October 2015 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
XZXin Zhang
Xin Zhang
YWYuxia Wu
Yuxia Wu
PRPengwei Ren
Pengwei Ren
XLXueting Liu
Xueting Liu
DKDeying Kang
Deying Kang
Objective: To explore the relationship between the external validity and the internal validity of hypertension RCTs conducted in China. Methods: Comprehensive literature searches were performed in Medline, Embase, Cochrane Central Register of Controlled Trials (CCTR), CBMdisc (Chinese biomedical literature database), CNKI (China National Knowledge Infrastructure/China Academic Journals Full-text Database) and VIP (Chinese scientific journals database) as well as advanced search strategies were used to locate hypertension RCTs. The risk of bias in RCTs was assessed by a modified scale, Jadad scale respectively, and then studies with 3 or more grading scores were included for the purpose of evaluating of external validity. A data extract form including 4 domains and 25 items was used to explore relationship of the external validity and the internal validity. Statistic analyses were performed by using SPSS software, version 21.0 (SPSS, Chicago, IL). Results: 226 hypertension RCTs were included for final analysis. RCTs conducted in university affiliated hospitals (P < 0.001) or secondary/tertiary hospitals (P < 0.001) were scored at higher internal validity. Multi-center studies (median = 4.0, IQR = 2.0) were scored higher internal validity score than single-center studies (median = 3.0, IQR = 1.0) (P < 0.001). Funding-supported trials had better methodological quality (P < 0.001). In addition, the reporting of inclusion criteria also leads to better internal validity (P = 0.004). Multivariate regression indicated sample size, industry-funding, quality of life (QOL) taken as measure and the university affiliated hospital as trial setting had statistical significance (P < 0.001, P < 0.001, P = 0.001, P = 0.006 respectively). Conclusion: Several components relate to the external validity of RCTs do associate with the internal validity, that do not stand in an easy relationship to each other. Regarding the poor reporting, other possible links between two variables need to trace in the future methodological researches.

5 January 2021 in Physical Review C
Verified
Journal Article
Open access
PDF file
YHY. Huang
Y. Huang
HZHua Zheng
Hua Zheng
RWRyoichi Wada
Ryoichi Wada
XLX. Liu
X. Liu
WLW. Lin
W. Lin
JNJ. B. Natowitz
J. B. Natowitz
Albergo thermometers with double isotope, isotone, and isobar yield ratio pairs with one proton and/or neutron difference are investigated. Without any extra sequential decay correction, a real temperature value of 4.9±0.5 MeV is deduced from the yields of the experimentally reconstructed primary hot intermediate mass fragments (IMFs) from Zn64+Sn112 collisions at 40 MeV/nucleon using the Albergo thermometer for the first time. An experimental sequential decay correction from the apparent temperatures to the real ones for 12 other reaction systems with different neutron-proton (N/Z) asymmetries in the same experiment, Zn70, Ni64 on Sn112,124, Ni58,64, Au197, and Th232 at 40 MeV/nucleon, is performed using an empirical correction factor approach of Tsang et al. [ Phys. Rev. Lett. 78, 3836 (1997)] with the deduced 4.9-MeV temperature value. The dependence of nuclear temperature on the source N/Z asymmetry is further investigated using these deduced real source temperature values from the present 13 systems. It is found that the deduced real source temperatures at the present source N/Z range show a rather weak dependence on the source N/Z asymmetry. By comparison between our previous results and those from other independent experiments, a consistent description for the N/Z asymmetry dependence of nuclear temperature is addressed.

30 August 2022 in medRxiv
Verified
Preprint
Open access
PDF file
YZYi Zhu
Yi Zhu
PRPengwei Ren
Pengwei Ren
SDSuhail A. Doi
Suhail A. Doi
LFLuis Furuya-Kanamori
Luis Furuya-Kanamori
LLLifeng Lin
Lifeng Lin
CXChang Xu
Chang Xu
Background: Data extraction is the foundation for research synthesis evidence, and it is often time- and labor-consuming, and prone to errors. Whilst data extraction errors frequently occur in the literature, an interesting phenomenon was observed that data extraction error tend to be more common in trials of pharmaceutical interventions compared to non-pharmaceutical ones. This phenomenon has not been verified by high-quality evidence, the elucidation of which would have implications for guidelines, practice, and policy. Methods and analyses: We propose a crossover, multicenter, investigator-blinded, trial to elucidate the potential variants on the data extraction error rates of meta-analyses with pharmaceutical against non-pharmaceutical interventions. Eligible 90 participants would be 2 nd year or above post-graduate students (e.g., masters, doctoral program). Participants will be randomized to one of the two groups to complete pre-defined data extraction tasks: 1) group A will contain 10 randomized controlled trials (RCTs) of pharmaceutical interventions; 2) group B will contain 10 RCTs of non-pharmaceutical interventions. Participants would then be assigned to the alternative group for another round of data extraction, after a 30 mins washout period. Finally, those participants assigned to A or B group will be further 1:1 randomly matched based on a random-sequenced number, for the double-checking process on the extracted data. The primary outcome will be the data extract error rates of pharmaceutical intervention group and non-pharmaceutical group, before the double-checking process, in terms of the cell level, study level, and participant level. The secondary outcome will be the data error error rates of pharmaceutical intervention group and non-pharmaceutical group, after the double-checking process, again, in terms of the cell level, study level, and participant level. Generalized linear mixed effects model (based on the above three levels) will be used to estimate the potential differences in the error rates, with a log link function for binomial data. Subgroup analyses will account for the following factors i.e., the experience of individuals on systematic reviews, and the time used for the data extraction. Ethics and dissemination: This study has been approved by the institutional review board of Anhui Medical University (No.83220405). Findings of the study will be presented at international scientific meetings, and publish in peer-reviewed academic journal. Trial registration: Chinese Clinical Trial Register Center (Identifier: ChiCTR2200062206). Strengths and limitations of the study: This will be the first trial to compare data extraction error rates in pharmaceutical intervention and non-pharmaceutical intervention studies for research synthesis. This will be the third randomized trial on the strategy of data extraction in the world and the first in the Asia-Pacific region. The use of a crossover design provides a valid way to reduce the potential impact of heterogeneous contexts of the studies and thus is expected to provide robust evidence to support better evidence synthesis practice. We will restrict the participants to 2 nd year post-graduate students or above to ensure the feasibility of the trial; this restriction will no doubt impact the representativeness of the samples. A group of useful strategies (eg. use U disk and isolate signal etc.) should be taken to minimize the impact of the possible sharing of the completed extraction table among the participants.